EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of PAR2 in MASLD Progression and HCC Development

Pietro Guerra iD, Patrizia Pontisso iD, Andrea Martini

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157076 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Pietro Guerra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. Hauptthemen laut MEDLINE: Receptor, PAR-2, Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Liver. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently become the leading cause of chronic liver disease and can progress to hepatocellular carcinoma (HCC) through multiple pathogenic mechanisms. Protease-activated receptor 2 (PAR2) is a G-protein-coupled receptor activated by proteases such as trypsin, tryptase or coagulation factors VII and Xa. Recent studies have shown that PAR2 expression is increased in the liver of patients with MASLD or liver fibrosis. Its activation is linked to metabolic dysfunction through several pathways, including SREBP1c activation, AMPK inhibition and Akt-induced insulin resistance. Inhibition of PAR2 has been effective in reducing MASLD progression in different animal models. Notably, PAR2 blockade has also been effective in more advanced stages of the disease by dampening chronic inflammation and fibrogenesis through the inhibition of hepatic stellate cell activation and of TGF-β and SerpinB3 production. PAR2 also plays a role in cancer development, promoting tumour proliferation, angiogenesis and expression of immune checkpoint inhibitors (like PD-L1, CD47 and CD24). Due to its multifaceted involvement in liver disease, PAR2 is emerging as a key therapeutic target in this clinical context. This review aims to summarise current knowledge on PAR2′s role in MASLD and its potential as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, PAR-2Carcinoma, HepatocellularLiver NeoplasmsFatty LiverHumansAnimalsDisease ProgressionLiver Cirrhosis

Stichwörter der Autor:innen

liver cancermetabolic dysfunctionprotease-activated receptor

Substanzen

Receptor, PAR-2

Autor:innen und Institutionen

  • Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
  • Azienda Ospedale-Università Padova, Via Giustiniani 2, 35128 Padova, Italy.

ORCID-Profile: Pietro Guerra, Patrizia Pontisso

Zitieren

APA

Guerra, P., Pontisso, P., & Martini, A. (2025). The Role of PAR2 in MASLD Progression and HCC Development. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157076

Vancouver

Guerra P, Pontisso P, Martini A. The Role of PAR2 in MASLD Progression and HCC Development. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157076

BibTeX
@article{Guerra2025,
  author = {Guerra, Pietro and Pontisso, Patrizia and Martini, Andrea},
  title = {The Role of PAR2 in MASLD Progression and HCC Development},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157076}
}
Kostenlos starten →